

PurifOH Limited

ABN: 11 124 426 339

Reporting Period: For the year ended 30 June 2024

Previous Period: For the year ended 30 June 2023

Principal Activities and Review of Operations

Results for Announcement to Market (unaudited)	\$ Change	% Change	12 months to 30 June 2024 \$	12 months to 30 June 2023 \$
Revenue from ordinary activities	(5,240)	(100.0%)	-	5,240
Profit/(loss) after tax from ordinary activities attributable to members	(129,729)	33.3%	(518,582)	(388,853)
Profit/(loss) attributable to members	(129,729)	33.3%	(518,582)	(388,853)

Earnings Per Share	30 June 2024 Cents	30 June 2023 Cents
Basic loss per share - weighted average	(1.612)	(1.217)
Diluted loss per share - weighted average	(1.612)	(1.217)

Dividend Information	Amount per share	Franked Amount per share
Dividend – current reporting period	Nil	Nil
Dividend – previous reporting period	Nil	Nil

Net Tangible Asset Backing per Ordinary Share	Cents
Net tangible asset backing per ordinary share – current reporting period	(10.65)
Net tangible asset backing per ordinary share – previous reporting period	(9.01)

Commentary on the Results for the Period

The loss results from normal operating expenses of the company associated with its ongoing research and development program for the Free Radical Generator.

Attachments

The following documents are attached:

- Explanation of Principal Activities and Review of Operations
- The Preliminary Final Report of PurifOH Limited for the year ended 30 June 2024

Audit Status

This Preliminary Final Report is based on the Annual Financial Report which is in the process of being audited.

Control gained over entities

None

Loss of control over entities

None

Current period

There were no dividends paid, recommended or declared during the current year.

Previous period

There were no dividends paid, recommended or declared during the previous period

Dividend reinvestment plans

None

Details of associates and joint venture entities

None

Foreign entities

None

Any other significant information

None



Carl Le Souef
Chairman

Dated this 30th day of August 2024

PuriflOH Limited (“PuriflOH”, “PO3” or “Company”), continues with the development of its Free Radical Generator (“FRG”) technology for a range of applications. The applications are broadly across three opportunities:

- Indoor air purification;
- Water sanitation; and
- Medical sterilisation.

The Company has been expanding the potential of the technology within these opportunities as well as considering additional opportunities within other sectors such as agriculture.

In continuing to move forward with the technology the Company has moved its R&D work to Australia under the oversight of Dr. Alex Sava and Mr. Vigneswaran Appia. To that end the ACERT Product has been developed to clean air-conditioning coils, a common source of air contamination within the home and office.

Further agreement has been reached with Osmoflo Limited to further explore the commercial opportunities of the FRG technology in the water sector, with specific interest in the destruction of PFAS and other speciality applications where existing solutions are not ideal.

About the FRG Technology

The FRG technology produces a range of Reactive Oxygen Species (“ROS”) that include the hydroxyl radical ($OH\cdot$), superoxide radical ($O_2^{\cdot-}$), oxygen radical ($O\cdot$) and the ozone molecule – all of which are amongst the most highly oxidative species known as indicated by the table below.

Oxidizing Agent	Oxidation Potential (V)
Fluorine	3.06
Hydroxyl radical	2.80
Oxygen (atomic)	2.42
Ozone	2.08
Hypochlorite	1.49
Chlorine	1.36
Hydrogen peroxide	1.78
Chlorine dioxide	1.27
➤ Oxygen (molecular)	1.23

The effectiveness of oxidising radicals in purification, sanitation and sterilisation has long been known. The challenge for widespread adoption has been reliable and cost-effective production of the radicals themselves. The radicals have a short half-life and as a result they cannot be stored nor transported. To deploy and maximise the power of these radicals requires a robust, reliable and cost effective in-situ production system.

The Company’s development program aims to provide systems with these characteristics. Using one flexible core technology, the objective of these applications is the purification of air, the purification of water and then ability to sterilize medical equipment and facilities.

During the year the Company focused on the development opportunities within the air, surface disinfection and water treatment sectors.

PURIFLOH LIMITED

Preliminary Final Report

30 June 2024

General Information

The financial statements cover PuriflOH Limited. They are presented in Australian dollars, which is PuriflOH Limited’s functional and presentation currency.

The preliminary financial statements were authorised for issue, in accordance with a resolution of directors, on 31 August 2024. The directors have the power to amend and reissue the financial statements.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the twelve months ended 30 June 2024

	Note	30 June 2024 \$	30 June 2023 \$
Revenue			
Revenue from continuing operations		-	5,240
Other Income			
Somnio Global – Debt forgiveness		-	431,157
Somnio Global Adjustment		381,319	-
Unrealised FX Gain		5,019	334,563
Total Revenue and Other Income		386,338	770,960
Accounting and audit	2	(156,744)	(157,815)
Other Expenses	2	(604,114)	(732,040)
Consultants expense		(54,348)	-
Consultants expense – share-based payments		-	(195,000)
Finance costs		(89,715)	(74,958)
Total expense		(904,921)	(1,159,813)
Profit/(Loss) before income tax		(518,583)	(388,853)
Income tax expense		-	-
Net profit/(Loss) for the period		(518,583)	(388,853)
Other Comprehensive Income			
Items that may be reclassified to profit or loss			
Exchange differences on translating foreign operations		(9,264)	(359,469)
Total Comprehensive Income/(Loss) for the period		(527,847)	(748,322)
Attributable to owners of the parent entity		(527,847)	(748,322)
Basic earnings Profit/(loss) per share (cents)		(1.612)	(1.217)
Diluted earnings Profit/(loss) per share (cents)		(1.612)	(1.217)

The Consolidated Statement of Profit or Loss and Other Comprehensive Income above should be read in conjunction with the accompanying notes.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2024

	Note	30 June 2024 \$	30 June 2023 \$
Assets			
Current Assets			
Cash and cash equivalents		4,962	9,239
Trade and other receivables		17,695	14,678
Prepayments		-	12,302
Total Current Assets		22,657	36,219
Non-Current Assets			
Intangible assets - trade marks		56,619	60,026
Total Non-Current Assets		56,619	60,026
Total Assets		79,276	96,245
Liabilities			
Current Liabilities			
Trade and other payables	3	2,313,663	1,700,343
Employee benefits		11,145	-
Somnio Global – success fee provision		-	377,074
Total Current Liabilities		2,324,808	2,077,417
Non-Current Liabilities			
Borrowings – Dilato		1,180,026	916,540
Total Non-Current Liabilities		1,180,026	916,540
Total Liabilities		3,504,834	2,993,957
Net Assets/(Liabilities)		(3,425,558)	(2,897,712)
Equity/ (Shareholders' Deficit)			
Contributed equity	4	84,547,846	84,547,846
Foreign exchange translation reserve		(498,533)	(489,270)
Accumulated losses		(87,474,871)	(86,956,288)
Total Equity/ (Shareholders' Deficit)		(3,425,558)	(2,897,712)

The Consolidated Statement of Financial Position above should be read in conjunction with the accompanying notes.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the 12 months ended 30 June 2024

	Contributed Equity	Foreign Currency Translation Reserve	Accumulated losses	Total
	\$	\$	\$	\$
Balance at 30 June 2023	84,547,846	(489,269)	(86,956,288)	(2,897,712)
Profit/(Loss) for the period	-	-	(518,583)	(518,583)
Other comprehensive income	-	(9,264)	-	(9,264)
Total comprehensive income (loss) for the period	-	(9,264)	(518,583)	(527,847)
Balance at 30 June 2024	84,547,846	(498,533)	(87,474,871)	(3,425,558)

For the 12 months ended 30 June 2023

	Contributed Equity	Foreign Currency Translation Reserve	Accumulated losses	Total
	\$	\$	\$	\$
Balance at 30 June 2022 (Restated)	84,352,846	(129,800)	(86,567,435)	(2,344,389)
Shares issued	195,000	-	-	195,000
Profit/(Loss) for the period	-	-	(388,853)	(388,853)
Other comprehensive income	-	(359,469)	-	(359,469)
Total comprehensive income (loss) for the period	-	(359,469)	(388,853)	(748,322)
Balance at 30 June 2023	84,547,846	(489,269)	(86,956,288)	(2,897,712)

The Consolidated Statement of Changes in Equity above should be read in conjunction with the accompanying notes.

CONSOLIDATED STATEMENT OF CASH FLOWS

For the 12 months ended 30 June 2024

	Note	30 June 2024 \$	30 June 2023 \$
<u>Cash flows related to operating activities</u>			
Receipts from customers		-	5,240
Payments for research and development and other expenditure		(177,906)	(212,279)
Net operating cash flows		(177,906)	(207,039)
<u>Cash flows related to financing activities</u>			
Proceeds from Dilato Facility		173,773	199,346
Net financing cash flows		173,773	199,346
Net increase / (decrease) in cash held		(4,133)	(7,693)
Net foreign exchange differences		(144)	20
Cash and cash equivalents at beginning of the period		9,239	16,912
Cash and Cash Equivalents at the end of the period		4,962	9,239

The Consolidated Statement of Cash Flows above should be read in conjunction with the accompanying notes.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1. General Information

PuriflOH Limited ("PuriflOH", "the Company" or "PO3") is a public company, incorporated and domiciled in Australia. The Company listed on the Australian Securities Exchange (ASX) on 30 December 2010.

Basis of Preparation – Accounting policies, estimation methods and measurement bases

These preliminary statements have been prepared in accordance with the ASX listing rules and do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the financial statements for the year ended 30 June 2024 and any public announcements made by the company during the reporting period in accordance with continuous disclosure requirements of the *Corporations Act 2001*.

Accounting policies, estimation methods and measurement bases used in this Appendix 4E are the same as those used in the last annual report and the last half-year report except as described below.

Going Concern

The Directors of the Group have prepared the Financial Report of the Group on a going concern basis which contemplates the continuity of normal business activity and the realisation of assets and settlement of liabilities in the normal course of business.

The Directors note that the report shows a net loss for the year of \$518,583 (2023: net loss of \$388,853) and a net operating cash outflow of \$177,906 (2023: outflow of \$207,039), and a net current asset deficiency of \$2,302,151 (30 June 2023: deficiency of \$2,041,198)

Notwithstanding the above, the Directors of the Group believe the going concern assumption remains appropriate as the continuation of the Group as a going concern is dependent upon its ability to achieve or maintain the following:

- The continued financial support from the Dilato loan facility as outlined below;
- The continued support of related creditors;
- The ability to raise additional capital or attract alternate sources of funding; and
- The generation of cash inflows resulting from successful engagement with OEM's.

The net current asset deficiency includes related party liabilities of \$2,272,371 (consisting of \$761,840 unpaid director fees and Dilato Investments Pty Ltd payable of \$1,385,680) the timing and form of settlement of which can be managed by the Directors.

Subsequent to the end of the year, on 22 July 2024, the Directors resolved to convert \$1,385,680 of the liabilities owed by PuriflOH to Dilato Investments Pty Ltd, \$1,200,934 in facility and interest liabilities owed to Dilato Holdings Pty Ltd, and \$486,090 of the liabilities owed to Directors Dr Sava and former Director Mr Jon Evans, to shares (subject to the shareholder approval at the next AGM).

The Company has continued to advance the commercial application of our innovative Free Radical Generation ("FRG") technology with a focus in the treatment of water, arguably the most significant sector of the applicable target market for the Company. The path to commercialisation entails a series of critical steps, including internal and external laboratory scale tests, collaborative efforts with Australian and American councils for pilot installations, and the development of tailored PFAS removal solutions for deployment worldwide and this has been progressing well. The Company is determined to work towards commercialisation of its technologies during the 2024 calendar year. While longer-term funding alternatives are being considered, the Company continued to retain the financial support of Dilato Holdings through extensions to their loan Agreement, currently until 31 December 2025.

Dilato Holdings Pty Ltd, a related entity, has provided a finance facility to the Group for a total of \$3,000,000. As at 30 June 2024, \$2,026,663 of this facility remains undrawn. The facility is unsecured, includes an interest rate of 10% and the maturity date is 31 December 2025. The Directors are not aware of any circumstances where this finance facility will not continue to be made available to the Group.

The Directors and management prepared a forecast, based on the group maintaining reduced ongoing operations, which demonstrates that there will be sufficient funding to operate for a period that is not less than twelve months beyond the date these financial statements are approved. Accordingly, the Directors believe that based on the above, and other strategies implemented, that the Company is able to continue to operate and meet its Going Concern obligations.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

2. Other Expenses and Accounting Expenses

Loss before income tax includes the following specific items:

Other Expenses	30 June 2024	30 June 2023
	\$	\$
ASX Fees	28,110	30,099
Share Registry Services	8,341	14,963
Serviced Office	90,000	90,000
Legal Fees	19,582	7,155
Insurance	11,132	66,805
Directors Fees	192,000	302,004
Salary, Wages, Leave	177,414	152,609
Other	77,535	68,405
	604,114	732,040

Accounting and Audit Expenses	30 June 2024	30 June 2023
	\$	\$
Accounting Fees	120,000	123,400
Audit Fees	36,744	34,415
	156,744	157,815

3. Current Liabilities

Current	30 June 2024	30 June 2023
	\$	\$
Trade payables (a)	109,763	14,991
Accruals	25,000	23,000
USA Trade and Other payables	31,380	31,352
Other related parties		
Directors' Fees	761,840	587,090
Somnio Payable	-	377,074
Dilato Payable	1,385,680	1,043,910
Balance	2,313,663	2,077,417

(a) Trade payables and other payables are non-interest bearing liabilities. All amounts are short term and the carrying values are considered to be a reasonable approximation of fair value.

4. Contributed Equity

	Note	30 June 2024	30 June 2023
		\$	\$
Ordinary shares		84,547,846	84,352,846
Share issue – share-based payment		-	195,000
Balance		84,547,846	84,547,846

5. Significant Events after Balance Sheet Date

On 19 June 2024, the Directors resolved to convert \$35,750 in consulting fees for services provided by Terra Australis to shares. (to be approved at the AGM post year-end)

On 22 July 2024, the Directors resolved to convert \$1,385,680 of the liabilities owed by PuriflOH to Dilato Investments Pty Ltd, \$1,200,934 in facility and interest liabilities owed to Dilato Holdings Pty Ltd, and \$486,090 of the liabilities owed to Directors Dr Sava and former Director Mr Jon Evans, to shares (subject to the shareholder approval at the next AGM).

No other matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

6. Interests in Subsidiaries

The consolidated financial statements include the financial statements of PuriflOH and its subsidiaries listed in the following table:

Name	Country of Incorporation	Equity Interest	
		2024	2023
PuriflOH USA Incorporated	United States	100%	100%

The Company has a US subsidiary called PuriflOH USA Incorporated. This subsidiary was incorporated in Delaware, USA in late 2018. The subsidiary carries a subscription of shares of common stock with par value of US\$0.001 of which PuriflOH Limited owns 100%. As a result of this establishment, the financial statements reflect the consolidation position of the parent and the subsidiary collectively as the Group.

The purpose of this entity is to manage operations in the US as the Company moves forward with its commercialization plans for the Free Radical Generator.

The financial statements above are currently in the process of being audited.

Signed



Carl Le Souef
Chairman

Dated this 30th day of August 2024